US 8536134
`US 20080009436
`US 8211855
`US 20080070834
`US 20120270805
`PRIORITY APPLN.
`INFO.:
`
`
`
`B2
`Al
`B2
`Al
`Al
`
`20130917
`20080110
`20120703
`20080320
`20121025
`
`US 2007-857223
`
`20070918
`
`20071115
`US 2007-940652
`20120628
`US 2012-13536479
`A2 20050713
`US 2005-181178
`A2 20050713
`US 2005-181187
`A2 20050713
`US 2005-181409
`A2 20050713
`US 2005-181428
`A2 20050713
`US 2005-181509
`A3 20051019
`US 2005-255821
`Al 20070918
`US 2007-857223
`
`
`
`
`ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
`
`AB
`
`
`
`
`
`
`A composition is disclosed herein comprising from about 0.001% to about 0.4%
`cyclosporin A, castor oil, and a surfactant selected from the group
`consisting of alc. ethoxylated, alcs., alkyl glycosides, alkyl
`
`polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers,
`carboxylated alc. or alkylphenol ethoxylates, carboxylic adds/fatty acids,
`
`cellulose derivs., ethoxylated alcs., ethoxylated alkylphenols,
`ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty
`acids, ethoxylated fatty esters and oils,
`fatty alcs., fatty esters,
`glycol esters,
`lanolin-based derivs.,
`lecithin and lecithin derivs.,
`lignin and lignin derivs., Me esters, monoglycerides and derivs.,
`phospholipids, polyacrylic acids, polyethylene glycols, polyethylene
`oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric
`surfactants, polypropylene oxides, propoxylated alcs., propoxylated alkyl
`phenols, propoxylated fatty acids, protein-based surfactants, sarcosine
`derivs., silicone-based surfactants, sorbitan derivs., stearates, sucrose
`and glucose esters and derivs., and combinations thereof.
`For example,
`emulsion was prepared containing cyclosporin A 0.1%, castor oil 1%, clove
`oil 0.7%, Polysorbate-80 1%, diglycerol 0.7%, glycerin 2%,
`CM-cellulose 0.5%,
`sodium hydroxide to adjust pH (7.2) and water as
`needed.
`
`
`
`THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
`OS.CITING REF COUNT:
`(2 CITINGS)
`
`
`
`THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS
`
`
`
`RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`
`
`
`
`
`
`1
`
`89
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`REFERENCE COUNT:
`
`Li
`ANSWER 5 OF 5
`
`ACCESSION NUMBER:
`
`
`
`DOCUMENT NUMBER:
`
`
`TITLE:
`
`INVENTOR(S):
`
`PATENT ASSIGNEE (S):
`SOURCE:
`
`
`
`COPYRIGHT 2013 ACS on STN
`CAPLUS
`2007:58577
`CAPLUS
`146:149007
`
`
`
`
`
`Composition comprising cyclosporin A
`
`Chang,
`James N.; Olejnik, Orest; Firestone, Bruce A.
`Allergan,
`Inc., USA
`PCT Int. Appl., 32 pp.
`CODEN: PIXXD2
`Patent
`
`English
`3
`
`DOCUMENT TYPE:
`
`LANGUAGE:
`FAMILY ACC. NUM. COUNT:
`PATENT INFORMATION:
`
`
`
`
`
`PATENT NO.
`KIND DATE
`APPLICATION NO.
`DATE
`
`WO 2006-US26881
`
`20060712
`
`A2
`WO 2007008894
`20070118
`A3
`WO 2007008894
`20070628
`
`
`W:
`AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
`
`CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
`GE, GH, GM, HN, HR, HU,
`ID,
`IL,
`IN,
`IS, JP, KE, KG, KM, KN, KP,
`KR, KZ, LA, LC, LK, LR, LS,
`LT,
`LU,
`LV,
`LY,
`MA,
`MD,
`MG, MK, MN,
`MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
`SC, SD, SE, SG, SK, SL,
`SM, SY, TJ,
`IM,
`IN, TR, TT, TZ, UA, UG,
`US, UZ, VC, VN, ZA, ZM,
`ZW
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`TEVA - EXHIBIT 1024 (PART 2 OF 4) Q9Q2
`
`0202
`
`TEVA - EXHIBIT 1024 (PART 2 OF 4)
`
`

`

`
`
`CI
`IE,
`RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
`IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, Bd,
`IS,
`CF, CG, CI, CM, GA, GN, GO, GW,
`ML,
`MR, NE, SN, TD, TG, BW, GH,
`
`LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
`GM, KE,
`2M, ZW, AM, AZ, BY,
`
`IM, AP, EA, EP, OA
`KG, KZ, MD, RU, TJ,
`US 20070015690
`Al
`20070118
`US 2005-181178
`US 7297679
`B2
`20071120
`US 20070015710
`Al
`20070118
`US 7276476
`B2
`20071002
`US 20070015691
`Al
`20070118
`US 20070015692
`Al
`20070118
`US 7202209
`B2
`20070410
`20050713
`US 2005-181509
`US 20070015693
`Al
`20070118
`20060712
`AU 2006-268264
`AU 2006268264
`Al
`20070118
`20060712
`CA 2006-2602452
`CA 2602452
`Al
`20070118
`
`
`20060712
`EP 2006-786892
`20080326
`EP 1901711
`A2
`
`
`
`
`
`
`
`
`IE,
`AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
`R:
`IS,
`IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
`JP 2009501228
`T
`20090115
`JP 2008-521528
`20060712
`BR 2006013533
`A2
`20110118
`BR 2006-13533
`20060712
`US 20070149447
`Al
`20070628
`US 2007-679934
`20070228
`US 8536134
`B2
`20130917
`US 20080070834
`Al
`20080320
`US 20080207494
`Al
`20080828
`US 8288348
`B2
`20121016
`PRIORITY APPLN.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`INFO.:
`
`
`
`
`
`
`
`
`
`
`
`US 2005-181187
`
`US 2005-181409
`US 2005-181428
`
`
`
`
`
`US 2007-940652
`US 2007-917448
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6
`
`
`
`US 2005-181178
`US 2005-181187
`US 2005-181409
`US 2005-181428
`US 2005-181509
`
`WO 2006-US26881
`
`
`
`ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
`
`AB
`
`
`
`
`
`
`
`
`
`20050713
`
`20050713
`
`20050713
`20050713
`
`20071115
`20071213
`
`20050713
`20050713
`20050713
`20050713
`20050713
`20060712
`
`A
`A
`A
`A
`A
`
`
`
`
`
`
`Cyclosporin A compns. are disclosed herein comprising an oil and a
`Thus,
`surfactant.
`These are useful
`in the treatment of dry eye disease.
`composition was prepared containing cyclosporin A 0.1, castor oil 1, clove oil
`0.7, polysorbate-80 1, diglycerol 0.7, glycerin 2, CM-cellulose 0.5
`
`
`and water as needed.
`
`
`
`
`
`THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
`OS.CITING REF COUNT:
`(6 CITINGS)
`
`=> d his
`
`
`
`
`
`(FILE 'HOME' ENTERED AT 23:44:39 ON 0Q1 OCT 2013)
`
`
`
`
`
`
`
`
`
`
`
`
`23:44:57 ON 01 OCT 2013
`FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS' ENTERED AT
`
` EMUL EN AND (GL
`
`5 CYCLOSPORIN AND CASTOR AND POLYSORBATE AND P
`YCERI
`
`
`
`
`
`
`
`
`L1
`
`
`
`
`
`
`=> logoff h
`COST IN U.S. DOLLARS
`
`
`
`FULL ESTIMATED COST
`
`
`
`
`
`
`
`
`
`
`MINUTES
`SESSION WILL BE HELD FOR 120
`
`SIN INTERNATIONAL SESSION SUSPENDED AT 23:48:15 ON 01 OCT 2013
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`SINCE FILE
` ENTRY
`
`37.83
`
`ESSION5
`
`TOTAL
`
`38.07
`
`0203
`
`0203
`
`

`

`
`
`Application/Control No.
`
`Search Notes
`
`13967163
`
`Applicant(s)/Patent Under
`Reexamination
`ACHEAMPONGETAL.
`
`1658
`
`ArtUnit
` | Examiner
`
`
`MARCELA M CORDERO GARCIA
`
`PoSymbotCate|Examiner
`|
`
`CPC- SEARCHED
`
`PoSymbotCate
`
`CPC COMBINATION SETS - SEARCHED
`
`pO
`
`|Class|CCSubclassCidECCiate|SExaminer__|
`10/2/2013|MMCG
`
`US CLASSIFICATION SEARCHED
`
`SEARCH NOTES
`
`Search Notes|Date
`STN search (attached)
`EASTupdated (attached)
`also ran PALM Inventor search
`
`
` US Subclass / CPC Group|Examiner—ceSymbolSymbol
`opesass|Class/
`
`INTERFERENCE SEARCH
`
`
`
`U.S. Patent and TrademarkOffice
`
`Part of Paper No.: 201807904
`
`0204
`
`

`

`Receipt date: 09/12/2013
`Doc description: Information Disclosure Statement (IDS) Filed
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH,
`
`/M.M.C.G/
`
`U.S.PATENTS
`
`Examiner Cite
`Initial
`No
`
`Patent Number
`
`Kind
`Code!
`
`Issue Date
`
`Nameof Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`3278447
`
`1966-10-11
`
`Thomas McNicholas
`
`4388229
`
`4388307
`
`1983-06-14
`
`Cherng-Chyi Fu
`
`1983-06-14
`
`Thomas Cavanak
`
`Delevallee etal
`
`4839342 aa
`
`Sk
`fe
`co4614736
`fe
`Sf
`aa
`fe
`
`4649047
`
`4764503
`
`4814323
`
`0205
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH,
`
`/M.M.C.G/
`
`4970076
`
`1990-11-13
`
`David Horrobin
`
`4990337
`
`1991-02-05
`
`Kurihara et al
`
`4996193
`
`1991-02-26
`
`Hewitt et al
`
`5047396
`
`1991-09-10
`
`Orban et al
`
`
`
`5342625
`
`5051402
`
`5053000
`
`5286730
`
`5286731
`
`5294604
`
`Nussenblatt et al
`
`5296158
`
`0206
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/MM.C.G/
`
`5368854
`
`5411952
`
`— ponte
`_— pent
`
`5424078
`
`1995-06-13
`
`Anthony Dziabo
`
`5474919
`
`Chartrain et al
`
`5474979
`
`5504068
`
`5614491 pm|
`
`pefome|
`pfem|
`pfe|
`fem|
`pefem|
`pm|
`pm|
`pf]
`per|
`med
`
`=
`
`ow
`
`B
`
`Oo)
`
`~
`
`co
`
`5540931
`
`5543393
`
`5589455
`
`5591971
`
`|— —
`
`-08-
`
`_ ee
`
`0207
`
`0207
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXGEPT WHERE LINED THROUGH.
`
`/M.M.C.G/
`
`5639724
`
`1997-06-17
`
`Thomas Cavanak
`
`
`
`5834017
`Nh&&wwwwWwwWwww=oOron)KRa
`
`5652212
`
`1997-07-29
`
`Cavanak et al
`
`ow
`
`5719123
`
`1998-02-17
`
`Morleyet al
`
`5739105
`
`_—
`
`aa
`
`5753166
`
`5766629
`
`~I
`
`co
`
`©
`
`5798333
`
`Bernard Sherman
`
`5807820
`
`5827822
`
`Floch'h et al
`
`5827862
`
`Yoshitaka Yamamura
`
`Cho etal
`
`0208
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH,
`
`/MM.C.G/
`
`Nh
`
`5843452
`
`5843891
`
`Bernard Sherman
`
`poefoesfo
`pwsfeesFO
`
`— —_—
`o1o1oi££&££££&~I&w
`
`5858401
`
`5866159
`
`5891846
`
`1999-04-06
`
`Ishida et al
`
`5916589
`
`1999-06-29
`
`Hauer et al
`
`5929030
`
`1999-07-27
`
`Hamied etal
`
`5951971
`
`5962014
`
`—_
`
`5962017
`
`—_
`
`aa
`
`oO
`
`co
`
`©
`
`oO
`
`=
`
`Nh
`
`5962019
`
`1999-10-05
`
`Choet al
`
`0209
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH,
`
`/M.M.C.G./
`
`— a SC
`
`5977066
`
`Hf|
`fee|
`ef|
`fem|
`
`—feed
`ef|
`
`6046163 mem|
`
`wR
`
`5981479
`
`—_ _
`
`aa
`
`5981607
`
`4999-11-09
`
`Dinget al
`
`U.S. Application No. 09/008,924 and
`its entire prosecution history
`
`5998365
`
`1999-12-07
`
`Bernard Sherman
`
`~I —
`
`
`
`-—
`
`Friedman etal
`
`—_ eeee
`
`-
`—_ a
`
`6008191
`
`©
`
`6008192
`
`=
`
`Nh
`
`6022852
`
`6024978
`
`fm]
`elem|
`mem|
`
`0210
`
`0210
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/M.M.C.G/
`
`—— /_ _— SC
`
`— _— oo
`— _ oo
`
`jen
`~“NNNNron)woN=aoO
`
`DpBK
`
`6159933
`
`2000-12-12
`
`Bernard Sherman
`
`6197335
`
`2001-03-06
`
`Bernard Sherman
`
`~I
`
`6254860
`
`6254885
`
`6267985
`
`2001-07-31
`
`Chen etal
`
`6284268
`
`_ —
`
`6294192
`
`— _
`
`6306825
`
`2001-10-23
`
`Thomas Cavanak
`
`6323204
`
`—
`
`my
`
`6346511
`
`2002-02-12
`
`Singh et al
`
`0211
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/MM.C.G/
`
`6350442
`
`6413547
`
`oO
`
`peesfee|
`poemfmee
`peesfom|
`
`_— —
`BR©olo)lee)ooco|~™~™oRo=o
`
`~
`
`co
`
`6420355
`
`6468968
`
`©
`
`6475519
`
`—
`
`6486124
`
`2002-11-26
`
`Olbrich etal
`
`6544953
`
`2003-04-08
`
`Tsuzukietal
`
`6555526
`
`ow
`
`6562873
`
`2003-05-13
`
`Olejnik et al
`
`6569463
`
`2003-03-27
`
`Patel et al
`
`6582718
`
`2003-06-24
`
`Yoichi Kawashima
`
`0212
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH,
`
`2003-12-02
`
`Benita etal
`
`2005-03-29
`
`Robert Lyons
`
`/M.V.C.G/
`
`2007-04-10
`
`James N. Chang
`
`U.S. Application No. 11/181,428 and
`its entire prosecution history
`
`2007-10-02
`
`Changetal
`
`U.S. Application No. 11/181,187 and
`its entire prosecution history
`
`2007-10-30
`
`Changetal
`
`U.S. Application No. 11/255,821 and
`its entire prosecution history
`
`7297679
`
`2007-11-20
`
`James Chang
`
`U.S. Application No. 11/181,178 and
`its entire prosecution history
`
`7501393
`
`2009-03-10
`
`Tien etal
`
`U.S. Application No. 11/161,218 and
`its entire prosecution history
`
`8211855
`
`2012-07-03
`
`Changetal
`
`U.S. Application No. 11/857,223 and
`its entire prosecution history
`
`8288348
`
`2012-10-16
`
`Changetal
`
`U.S. Application No. 11/917,448 and
`its entire prosecution history
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`.
`
`Initial*
`
`a
`
`Number
`
`
`
`Code'| Date
`
`of cited Document
`
`0213
`
`pe6656460
`a6872705
`a7202209
`pe7276476
`pe7288520
`fe
`ke
`fe
`fe
`
`Figures Appear
`
`
`
`.
`
`ae
`
`.
`
`Pages,Columns,Lines where
`
`fouPublication Kind|Publication NameofPatenteeorApplicant RelevantPassagesorRelevant
`
`0213
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
` of
`
`pewsfeesfe
`Sp
`poeumesfo
`posseuofo
`Sp
`pewsfeeFO
`of
`posfamefo
`of
`ponefumeFO
`pfere
`pawsfumesfo
`Sof
`ponsfawnfo
`of
`Sf
`poe
`a
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/MM.C.G/
`
`Yoichi Kawashima
`
`Petszulat et al
`
`posfernsfo
`
`0214
`
`0214
`
`

`

`| N
`
`hNoNoN=====oo|&
`
`= w
`
`aa
`
`2003-03-20
`
`Stergiopoulosetal
`
`= Oo
`
`20030059470
`
`2003-03-27
`
`Rainer Muller
`
`20030060402
`
`2003-03-27
`
`Cavanak et al
`
`=
`
`20030087813
`
`_
`
`20030104992
`
`20030108626
`
`20030109425
`
`20030109426
`
`© =o N
`
`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENGES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/M.M.C.G/
`
`h
`
`0215
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`tnoscmrenrs
`|ter
`20070299004 ae
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/M.M.C.G/
`
`N ow
`
`20030133984
`
`2003-07-17
`
`Ambuhl et al
`
`NoB
`
`20030143250
`
`_
`
`20030147954
`
`2003-08-07
`
`Yang et al
`
`aa
`
`20030166517
`
`Nh ~
`
`20050014691
`
`Sfame
`
`20050059583
`
`No ©
`
`20070015691
`
`scene,
`
`20070027072
`
`eee
`eee
`
`20070087962
`
`aNh
`
`20070149447
`
`score,parast on
`
`ow ww
`
`hearer
`
`weet,aa
`
`0216
`
`0216
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXGEPT WHERE LINED THROUGH,
`
`/M.M.C.G./
`
`20080039378
`
`2008-02-14
`
`Graham etal
`
`U.S. Application No. 11/781,095 and
`its entire prosecution history**
`
`20080070834
`
`2008-03-20
`
`Changetal
`
`U.S. Application No. 11/940,652 and
`its entire prosecution history
`
`20080146497
`
`2008-06-19
`
`Graham et al
`
`U.S. Application No. 11/858,200 and
`its entire prosecution history
`
`20080207495
`
`2008-08-28
`
`Graham et al
`
`U.S. Application No. 12/035,698 and
`its entire prosecution history
`
`20090131307
`
`2009-05-21
`
`Tien etal
`
`U.S. Application No. 12/361,335 and
`its entire prosecution history
`
`20100279951
`
`2010-11-04
`
`Morganet al
`
`U.S. Application No. 121771,952 and
`its entire prosecution history
`
`20110009339
`
`2011-01-13
`
`Rhett Schiffman
`
`U.S. Application No. 12/759,431 and
`its entire prosecution history**
`
`20110294744
`
`2011-12-01
`
`Morganet al
`
`U.S. Application No. 19/115,764 and
`its entire prosecution history
`
`20120270805
`
`2012-10-25
`
`Changetal
`
`U.S. Application No. 13/536,479 and
`its entire prosecution history
`
`2013-03-07
`
`Changetal
`
`U.S. Application No. 19/649,287 and
`its entire prosecution history
`
`
`
`20130059796
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.
`
`FOREIGN PATENT DOCUMENTS
`
`0217
`
`0217
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`.
`( Not for submission under 37 CFR 1.99)
`
`Ant
`
`Uni
`rt Unit
`
`ACHEAMPONG, ANDREW
`
`1653
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`QO°a @S
`
`prosfemme|
`pewsfume
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`/M.M.C.G/
`Nameof Patentee or
`Pages, Columns, Lines
`Publication
`where Relevant
`Applicantof cited
`Passages or Relevant
`Date
`
`Document
`.
`Figures Appear
`
`
`
`Initial* No|Numbers Code?!
`
`faeForeignDocument
`
`Country
`
`mea a1999-09-16
`
`Universitat Tubingen
`Universitatskl
`
`Won Jin Biopharma Co.,
`Ltd
`
`“_ a
`
`Transneuronix, Inc.
`
`—_— a
`
`0218
`
`2002-049603
`
`.Paa
`
`)
`
`0218
`
`

`

`
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`.
`( Not for submission under 37 CFR 1.99)
`
`Ant
`
`Uni
`rt Unit
`
`ACHEAMPONG, ANDREW
`
`1653
`
`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`Examiner Name
`
`TBD
`
`Attorney Docket Number
`
`17618-US-BCON6-AP
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. M.M.C.G/
`
`12
`
`2003-053405
`
`WO
`
`Yissum Research
`
`2003-07-03
`
`Development Company o
`the Hebrew
`
`If you wish to add additional Foreign Patent Documentcitation information please click the Add button
`
`NON-PATENT LITERATURE DOCUMENTS
`
`,
`,
`Examiner] Cite
`No
`Initials
`
`Include nameof the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`publisher, city and/or country where published.
`
`ABDULRAZIK, M. ET AL, Ocular Delivery of Cyclosporin A II. Effect of Submicron Emulsion's Surface Charge on
`Ocular Distribution of Topical Cyclosporin A, S.T.P. Pharma Sciences, Dec. 2001, 427-432, 11(6)
`
`ACHEAMPONG, ANDREW ETAL, Cyclosporine Distribution into the Conjunctiva, Cornea, Lacrimal Gland and
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog and Human eyes, 1996, 179
`
`ACHEAMPONG, ANDREW ETAL, Cyclosporine Distribution Into The Conjunctiva, Cornea, Lacrimal Gland, and
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes, Adv. Exp. Med. Biol.,
`1998, 1001-1004, 438
`
`ACHEAMPONG, ANDREW ETAL, Distribution of Cyclosporin A in Ocular Tissues After Topical Administration to
`Albino Rabbits and Beagle Dogs, Current Eye Research, 1999, 91-103, 18(2)
`
`AKPEK, ESEN KARAMURSEL ETAL, A Randomized Trial of Topical Cyclosporin 0.05% in Topical Steroid-Resistant
`Atopic Keratoconjunctivitis, Ophthalmology, 2004, 476-482, 111
`
`ANGELOV,O. ET AL, Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion, Adv Exp MedBiol, 1998,
`991-995, 438
`
`ANGELOV, O. ET AL, Safety Assessment of Cyclosporine Ophthalmic Emulsion in Rabbits and Dogs, XIth Congress
`
`— med— er_|fe
`
`of the European Society of Ophthalmology, 1997, 25-28, 1-5, Soc. Ophthalmol Eur., HU
`
`0219
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`
`
`Res, 1997, 1 page, 14 (11)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/M.N.C.G,/
`
`ARDIZZONE, SANDRO ETAL, A Practical Guide to the Management of Distal Ulcerative Colitis, Drugs, 1998,
`519-542, 55(4)
`
`BANIC, MARKO ETAL, Effect of Cyclosporine in a Murine Model of Experimental Colitis, Digestive Diseases and
`Sciences, June 2002, 1362-1368, 47(6)
`
`BONINI, S. ET AL, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18
`
`BREWSTER, MARCUS ETAL, Enhanced Delivery of Ganciclovir to the Brain Through the Use of Redox Targeting,
`Antimicrobial Agents and Chemotherapy, Apr 1994, 817-823, 38(4)
`
`BREWSTER, MARCUS ETAL, Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl-R-cyclodextrin-
`Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions,
`Journal of Pharmaceutical Sciences, March 1997, 335-339, 86(3)
`
`BREWSTER, MARCUS ETAL, Preparation, Characterization, and Anesthetic Properties of 2-Hydroxypropyl-f-
`cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse, Journal of Pharmaceutical Sciences,
`October 1995, 1154-1159, 84(10)
`
`BRINKMEIER, THOMASETAL, Pyodermatitis-Pyostomatitis Vegetans: A Clinical Course of Two Decades with
`Response to Cyclosporine and Low-Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81
`
`CASTILLO, JOSE M. BENITEZ DEL ETAL, Influence of Topical Cyclosporine A and Dissolvent on Corneal Epithelium
`Permeability of Fluorescein, Documenta Ophthalmologica, 1995, 49-55, 91
`
`CHEEKS, LISA ETAL, Influence of Vehicle and Anterior Chamber Protein Concentration on Cyclosporine Penetration
`Through the Isolated Rabbit Cornea, Current Eye Research, 1992, 641-649, 11(7)
`
`Database WPI Week 200044, Derwent Pub. Ltd., London, GB; An 2000-492678 & JP2000/143542, 2000, 2 Pages
`
`DING, SHULIN ET AL, Cyclosporine Ophthalmic O/W emulsion: Formulation and Emulsion Characterization, Pharm
`
`0220
`
`

`

` ©
`
`NNhNO=o1&oo
`
`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH,
`
`/M.M.C.G//
`
`DONNENFELD, ERIC D., The Economics Of Using Restasis, Ophthalmology Management, 10/2003, 3 pages, US
`
`DROSOS, A. A. ET AL, Efficacy and Safety of Cyclosporine-A Therapy for Primary Sjogren's Syndrome, Ter. Arkh.,
`1998, 77-80, 60(4)
`
`DROSOS, A.A. ET AL, Cyclosporin A Therapy in Patients with Primary Sjogren's Syndrome: Results at One Year,
`Scand J Rheumatology, 1986, 246-249, 61
`
`EISEN, DRORE ETAL, Topical Cyclosporine for Oral Mucosal Disorders, J Am Acad Dermatol, Dec. 1990,
`1259-1264, 23
`
`EPSTEIN, JOEL ET AL, Topical Cyclosporine in a Bioadhesive for Treatment of Oral Lichenoid Muscosal Reactions,
`Oral Surg Oral Med Oral Pathol Oral, 1996, 532-536, 82
`
`ERDMANN, S. ET AL, Pemphigus Vulgaris Der Mund- Und Kehlkopfschleimhaut Pemphigus Vulgaris of the Oral
`Mucosaand the Larynx, H+G Zeitschrift Fuer Hautkrankheiten, 1997, 283-286, 72(4)
`
`FDA Concludes Restasis (Cyclosporine) Not Effective for Dry Eye (6/18/1999). Accessed online at http:/Avww.
`dryeyeinfo.org/Restasis_Cyclosporine.htm on 8/14/09. 1 Page
`
`GAETA, G.M. ET AL, Cyclosporin Bioadhesive Gel in the Topical Treatment of Erosive Oral Lichen Planus,
`International Journal of Immunopathology and Pharmacology, 1994, 125-132, 7(2)
`
`GIPSON, ILENE ET AL, Character of Ocular Surface Mucins and Their Alteration in Dry Eye Disease, The Ocular
`Surface, April 2004, 131-148, 2(2)
`
`GREMSE, DAVID ET AL, Ulcerative Colitis in Children, Pediatr Drugs, 2002, 807-815, 4(12)
`
`GUNDUZ, KAAN ETAL, Topical Cyclosporin Treatment of Keratoconjunctivitis Sicca in Secondary Sjogren's
`Syndrome, Acta Ophthalmologica, 1994, 438-442, 72
`
`N oO
`
`No =
`
`NNh
`
`NOo)
`
`Nh ~
`
`N co
`
`No ©
`
`0221
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. MMO.G/
`
`w oO
`
`http:/Aweb.archive.org/web/2001030625323/http://www.surfactant.co.kr/surfactants/pegester.html, 2001, 6 Pages,
`retrieved on 7/05/2008
`
`
`
`LOPATIN, D.E., Chemical Compositions and Functions of Saliva, 8/24/2001, 31 Pages
`
`HUNTER, P.A. ET AL, Cyclosporin A Applied Topically to the Recipient Eye Inhibits Corneal Graft Rejection, Clin Exp
`Immunol, 1981, 173-177, 45
`
`JUMAA, MUHANNADETAL, Physicochemical Properties and Hemolytic Effect of Different Lipid Emulsion
`Formulations Using a Mixture of Emulsifiers, Pharmaceutica Acta Helvetiae, 1999, 293-301, 73
`
`KANAI, A. ET AL, The Effect on the Cornea of Alpha Cyclodextrin Vehicle for Eye Drops, Transplantation Proceedings,
`Febraury 1989, 3150-3152, Vol. 21
`
`KANPOLAT, AYFER ETAL, Penetration of Cyclosporin A into the Rabbit Cornea and Aqueous Humor after Topical
`Drop and Collagen Shield Administration, Cornea/External Disease, April 1994, 119-122, 20(2)
`
`KAUR, RABINDER ETAL, Solid Dispersions of Drugs in Polyocyethylene 40 Stearate: Dissolution Rates and Physico-
`Chemical Interactions, Journal of Pharmacy and Pharmacology, December 1979, 48P
`
`KUWANO, MITSUAKI ET AL, Cyclosporine A Formulation Affects Its Ocular Distribution in Rabbits, Pharmaceutical
`Research, January 2002, 108-111, 19(1)
`
`Lambert Technologies Corp. Material Safety Data Sheet for LUMULSE ™ POE-40 MS KP, last revision 8/22/2003. 3
`pages
`
`LEIBOVITZ, Z. ET AL., Our Experience In Processing Maize (Corn) Germ Oil, Journal Of The American Oil Chemists
`Society, 02/1983, 395-399, 80 (2), US
`
`LIXIN, XIE ET AL, Effect Of Cyclosporine A Delivery System in Corneal Transplantation, Chinese Medical Journal,
`2002, 110-113, 115 (1), US
`
`ow
`
`aNh
`
`ow ww
`
`www
`
`ow “J
`
`w Co
`
`ow oO
`
`th oO
`
`0222
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/M.M.C.G./
`
`XS
`
`LYONS, R.T. ET AL, Influence of Three Emulsion Formulation Parameters on the Ocular Bioavailability of
`Cyclosporine A in Albino Rabbits, Am Assoc Pharm Sci, 2000, 1 Page, 2(4)
`
`
`
`oi
`ppp=Noa=
`
`iNo
`
`B oo
`
`‘KR
`
`th oo
`
`tS oO
`
`o1 oO
`
`PEDERSEN, ANNE MARIE ETAL, Primary Sjogren's Syndrome: Oral Aspects on Pathogenesis, Diagnostic Criteria,
`Clinical Features and Approaches for Therapy, Expert Opin Pharma, 2001, 1415-1436, 2(9)
`
`PHILLIPS, THOMASETAL, Cyclosporine Has a Direct Effect on the Differentiation of a Mucin-Secreting Cell Line,
`Journal of Cellular Physiology, 2000, 400-408, 184
`
`PRESENT, D.H. ET AL, Cyclosporine and Other Immunosuppressive Agents: Current and Future Role in the
`Treatment of Inflammatory Bowel Disease, American Journal of Gastroenterology, 1993, 627-630, 88(5)
`
`Restasis ® Product Information Sheet, Allergan, Inc., 2009, 5 Pages
`
`Restasis® Increasing Tear Production, Retrieved on 08/14/2009, http://www.restasisprofessional.com/_clinical/
`clinical_increasing.htm 3 pages
`
`ROBINSON, N.A. ET AL, Desquamative Gingivitis: A Sign of Mucocutaneous Disorders - a Review, Australian Dental
`Journal, 2003, 205-211, 48(4)
`
`RUDINGER, J., Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence, Peptide
`Hormones, 1976, 1-7
`
`SALL, KENNETH ETAL, Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic
`Emulsion in Moderate to Severe Dry Eye Disease, Ophthalmology, 2000, 631-639, 107
`
`SANDBORN, WILLIAM ETAL, A Placebo-Controlled Trial of Cyclosporine Enemasfor Mildly to Moderately Active
`Left-Sided Ulcerative Colitis, Gastroenterology, 1994, 1429-1435, 106
`
`SANDBORN, WILLIAM ET AL, Cyclosporine Enemas for Treatment-Resistant, Mildly to Moderately Active, Left-Sided
`Ulcerative Colitis, American Journal of Gastroenterology, 1993, 640-645, 88(5)
`
`0223
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`
`
`Ophthalmol Vis Sci, Aug. 1998, 1551-1559, 39(9)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH,
`
`/M.M.C.G/
`
`SCHWAB, MATTHIAS ET AL, Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease, Clin
`Pharm, 2001, 723-751, 60(10)
`
`SECCHI, ANTONIO ETAL, Topical Use of Cyclosporine in the Treatment of Vernal Keratoconjunctivitis, American
`Journal of Ophthalmology, December 1990, 641-645, 110
`
`SMALL, DAVE ET AL, The Ocular Pharmacokinetics of Cyclosporine in Albino Rabbits and Beagle Dogs, Ocular Drug
`Delivery and Metabolism, 1999, 54
`
`SMALL, DAVID ET AL, Blood Concentrations of Cyclosporin A During Long-Term Treatment With Cyclosporin A
`ophthalmic Emulsions in Patients with Moderate to Severe Dry Eye Disease, Journal of Ocular Pharmacology and
`Therapeutics, 2002, 411-418, 18(5)
`
`SMILEK, DAWNETAL, A Single Amino Acid Change in a Myelin Basic Protein Peptide Confers the Capacity to
`Prevent Rather Than Induce Experimental Autoimmune Encephalomyelitis, Proc. Natl. Acad. Sci., Nov 1991,
`9633-9637, 88
`
`STEPHENSON, MICHELLE, The Latest Uses Of Restasis, Review Of Ophthalmology, 12/30/2005, 7 Pages, US
`
`STEVENSON, DARAETAL, Efficacy and Safety of Cyclosporin A ophthalmic Emulsion in the Treatment of Moderate-
`to-Severe Dry Eye Disease, Ophthalmology, 2000, 967-974, 107
`
`TESAVIBUL, N. ET AL, Topical Cyclosporine A (CsA) for Ocular Surface Abnormalities in Graft Versus Host Disease
`Patients, Invest Ophthalmol Vis Sci, Feb 1996, $1026, 37(3)
`
`The Online Medical Dictionary, Derivative, Analog, Analogue, Xerostomia, accessed 7/7/2005 and 7/13/2005, 6 Pages
`
`TIBELL, A. ET AL., Cyclosporin A In Fat Emulsion Carriers: Experimental Studies On Pharmacokinetics And Tissue
`Distribution, Pharmacology & Toxicology, 1995, 115-121, 76, US
`
`TSUBOTA, KAZUO ETAL, Use of Topical Cyclosporin A in a Primary Sjogren's Syndrome Mouse Model, Invest
`
`0224
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`. Re-Examination Application: 90/009,944 Filed on August, 27, 2011
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. MM.C.G/
`
`VAN DER REIJDEN, WILLY ET AL, Treatment of Oral Dryness Related Complaints (Xerostomia) in Sjogren's
`Syndrome, Ann Rheum Dis, 1999, 465-473, 58
`
`WINTER, T.A. ET AL, Cyclosporin A Retention Enemasin Refractory Distal Ulcerative Colitis and 'Pouchitis', Scand J
`Gastroenterol, 1993, 701-704, 28
`
`. Pending Application: 13/967,189 Filed on August 14, 2013
`
`. Pending Application: 13/976,179 Filed on August 14, 2013
`
`. Pending Application: 13/961 ,818 Filed on August 07, 2013
`
`. Pending Application: 13/961 ,835 Filed on August 07, 2013
`
`. Pending Application: 13/961 ,808 Filed on August 07, 2013
`
`. Pending Application: 13/961 ,828 Filed on August 07, 2013
`
`. Pending Application: 13/967,168 Filed on August 14, 2013
`
`If you wish to add additional non-patentliterature document citation information please click the Add button
`
`0225
`
`0225
`
`

`

`Receipt date: 09/12/2013
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`13967163
`
`13967163 - GAU: 1658
`
`
`if English languagetranslation is attached.
`
`ngio7ion4
`Date Considered
`Marcela Cordero Garola/
`Examiner Signature
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/M.M.C.G./
`
`EXAMINER SIGNATURE
`
`? Enter office that issued the document, by the two-letter code (WIPO
`2OVor MPEP 901.04.
`1 See Kind Codes of USPTO Patent Documentsat iw
`Standard ST.3).
`3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.
`5 Applicant is to place a check mark here
`
`0226
`
`0226
`
`

`

`Receipt date: 09/12/2013
`
`13967163
`
`13967163 - GAU: 1658
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT |,
`Ne
`( Not for submission under 37 CFR 1.99)
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`[-]
`
`That each item of information contained in the information disclosure statement wasfirst cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1).
`
`VA 22313-1450.
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public whichis to file (and by the USPTOto process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending uponthe individual case. Any comments on the amount of time you
`require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND
`FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was Known to
`any individual designated in 37 CFR 1.56(c) more than three monthsprior to the filing of the information disclosure
`statement. See 37 CFR 1.97(e)(2).
`
`L]
`
`** Signature indicates consideration of publication and file history. The Examiner has accessto these materials through the PTO computer
`systems. If additional copies are desired, please notify the Applicants through their attorneys.
`
`[_] See attached certification statement.
`[_] Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`DX] None
`
`SIGNATURE
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`Name/Print
`
`Registration Number
`
`68,681
`
`0227
`
`0227
`
`

`

`Receipt date: 09/12/2013
`
`13967163 - GAU: 1658
`
`Privacy Act Statement
`
`The information provided by youin this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
`(5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
`Department of Justice to